Om Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$80,510	19
2023	Research	$87,654	18
2022	Research	$93,410	9
2021	Research	$137,841	10
2020	Research	$14,330	4
2019	Research	$284,059	30

Breakdown

Who paid Research payments · program years 2019–2024

Celgene Corporation $362,534 40 payments
Allergan Inc. $186,103 24 payments
AstraZeneca Pharmaceuticals LP $136,286 13 payments
Ipsen Bioscience Inc $12,850 12 payments
Amgen Inc. $30 1 payment

Studies the money was for Research payments · program years 2019–2024

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis. $121,996 13 payments
PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) $65,273 6 payments
A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $56,135 5 payments
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele $42,244 1 payment
A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $35,863 7 payments
Phase III Study - Long Term Extension/Rollover from EE-001 - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagiti $33,609 2 payments
A 54 Week Treatment, Multicenter, Randomized, Double Blind, Double Dummy, Placebo and Active Controlled, Parallel Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis $31,310 3 payments
PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) (BMS Study Number: IM047-P15) (RPC01-3202) $31,013 2 payments
PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) (RPC01-3102) $29,205 1 payment
A Multi-Center, Multi-National, Randomized, Double - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects wit $25,210 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.